About Eyestem
Eyestem is a company based in Bengaluru (India) founded in 2015 by Rajarshi Pal, Jogin Bhairav Desai, Rajani Ravindra Battu, and Dhruv Sareen.. Eyestem has raised $19.95 million across 7 funding rounds from investors including Kotak Mahindra Bank, Biological E and Natco Pharma. The company has 1 employees as of March 29, 2024. Eyestem offers products and services including Eyecyte-RPE TM and Eyecyte-PRP TM. Eyestem operates in a competitive market with competitors including Annexon, Aldeyra, Nicox, Blue Rock Therapeutics and Gyroscope, among others.
- Headquarter Bengaluru, India
- Employees 1 as on 29 Mar, 2024
- Founders Rajarshi Pal, Jogin Bhairav Desai, Rajani Ravindra Battu, Dhruv Sareen
- Stage Minicorn
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Eyestem Research Private Limited
- Date of Incorporation 25 Aug, 2015
- Jurisdiction Bangalore, Karnataka, India
-
Annual Revenue
$40.09 K (USD)34.43as on Mar 31, 2020
-
Net Profit
$-466.72 K (USD)-102.22as on Mar 31, 2020
-
EBITDA
$-505.45 K (USD)-93.98as on Mar 31, 2020
-
Total Equity Funding
$19.95 M (USD)
in 7 rounds
-
Latest Funding Round
$10 M (USD), Series B
Aug 11, 2025
-
Investors
Kotak Mahindra Bank
& 20 more
-
Employee Count
1
as on Mar 29, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Eyestem
Eyestem offers a comprehensive portfolio of products and services, including Eyecyte-RPE TM and Eyecyte-PRP TM. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treats Dry AMD by restoring retinal pigment epithelium in patients.
Addresses Retinitis Pigmentosa through cell replacement for vision rescue.
Funding Insights of Eyestem
Eyestem has successfully raised a total of $19.95M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $10 million completed in August 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Series B — $10.0M
-
First Round
First Round
(28 Oct 2016)
- Investors Count 21
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2025 | Amount | Series B - Eyestem | Valuation |
investors |
|
| Aug, 2022 | Amount | Series A - Eyestem | Valuation | Biological E , Alkem Laboratories | |
| May, 2021 | Amount | Seed - Eyestem | Valuation | Endiya Partners |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Eyestem
Eyestem has secured backing from 21 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Kotak Mahindra Bank, Biological E and Natco Pharma. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage venture capital investing in AI, deep tech, healthcare, and fintech startups.
|
Founded Year | Domain | Location | |
|
Bioscience research, innovation, and entrepreneurship facilitation in life sciences are conducted in India.
|
Founded Year | Domain | Location | |
|
Seed-stage investments are targeted by Jacesa Investments venture capital firm.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Eyestem
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Eyestem
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Eyestem Comparisons
Competitors of Eyestem
Eyestem operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Annexon, Aldeyra, Nicox, Blue Rock Therapeutics and Gyroscope, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| domain | founded_year | HQ Location |
Drug candidates for immune-mediated diseases are developed by Aldeyra.
|
|
| domain | founded_year | HQ Location |
Nitric oxide-based therapeutics for glaucoma and eye conditions are developed.
|
|
| domain | founded_year | HQ Location |
Stem cell therapies are developed for cardiovascular and neurological diseases.
|
|
| domain | founded_year | HQ Location |
Mobile SDK developed for app engagement and monetization strategies.
|
|
| domain | founded_year | HQ Location |
Gene therapies for ocular and neurodegenerative diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Eyestem
Frequently Asked Questions about Eyestem
When was Eyestem founded?
Eyestem was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Where is Eyestem located?
Eyestem is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Who is the current CEO of Eyestem?
Jogin Bhairav Desai is the current CEO of Eyestem. They have also founded this company.
Is Eyestem a funded company?
Eyestem is a funded company, having raised a total of $19.95M across 7 funding rounds to date. The company's 1st funding round was a Seed of $479.19K, raised on Oct 28, 2016.
How many employees does Eyestem have?
As of Mar 29, 2024, the latest employee count at Eyestem is 1.
What is the annual revenue of Eyestem?
Annual revenue of Eyestem is $40.09K as on Mar 31, 2020.
What does Eyestem do?
Eyestem was founded in 2015 in Bengaluru, India, within the biotechnology sector. Cell replacement therapies targeting ophthalmological conditions, such as dry age-related macular degeneration, are developed. The product Eyecyte-RPE consists of a suspension of retinal pigment epithelium cells derived from human induced pluripotent stem cells. Damaged retinal cells are replaced through this approach, with operations centered on advancing treatments for vision-related disorders in the Indian and global markets.
Who are the top competitors of Eyestem?
Eyestem's top competitors include Annexon, Alimera Sciences and MeiraGTx.
What products or services does Eyestem offer?
Eyestem offers Eyecyte-RPE TM and Eyecyte-PRP TM.
Who are Eyestem's investors?
Eyestem has 21 investors. Key investors include Kotak Mahindra Bank, Biological E, Natco Pharma, Alkem Laboratories, and C-CAMP.
What is Eyestem's valuation?
The valuation of Eyestem is $42.7M as of Aug 2022.